Answers are grounded in this paper and cite their sources.
Objectives To describe the patterns of vasopressin use and the effect of timing in critically ill children. Methods Retrospective study between 2017 - 2023 in children less than 18 years old in a tertiary paediatric intensive care unit (PICU). Results Vasopressin was administered in 453/10,750 (4%) of admissions and of these 453, 43% had congenital heart disease and 21% had sepsis. The median starting dose was 0.02 Units/kg/hr [IQR;0.02–0.04] and vasopressin was commenced 13.9 h [IQR;2.5–67.7] after admission. Vasopressin was commenced within 24 h of noradrenaline initiation in 406 admissions. The median time from noradrenaline to vasopressin initiation was 4 h [IQR 16.3–0.5] and the median noradrenaline dose at vasopressin initiation was 0.15 µg/k/min [IQR 0.1–0.25]. Noradrenaline was able to be reduced following initiation of vasopressin, irrespective of timing between the two drugs. In an exploratory, multivariable logistic regression analysis, shorter time between noradrenaline and vasopressin initiation, measured continuously, was associated with reduced mortality (adjusted OR 0.94 [95%CI 0.91–0.98]). Arrhythmias, gastrointestinal and limb ischaemia during admission were higher in children who received vasopressin. Conclusions Vasopressin is administered to 4% of admissions to a large tertiary PICU; commonly in sepsis and congenital heart disease. After vasopressin initiation, noradrenaline dose decreased irrespective of timing after noradrenaline, however, earlier timing may be associated with reduced mortality.
No takes yet. Share an insight, caveat, or question.
Gelbart et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: